Product Details
| Product Name:
FDW028 |
CAS No.:
2768426-49-7 |
| Purity:
99.55% |
Supply Ability:
10g |
| Release date:
2026/06/15 |
Product Introduction
Bioactivity
| Name | FDW028 |
| Description | FDW028 is a selective and potent fucosyltransferase 8 (FUT8) inhibitor with anti-tumor activity that drives B7-H3 lysosomal degradation via defucosylation and CMA pathways. FUT8 can be used to study metastatic colorectal cancer (mCRC). |
| In vitro | METHODS: FDW028 (0.316-316μM, 72 hours) was used to treat SW480 and HCT-8 cells, and cell viability was detected with or without FUT8 knockdown.
RESULTS:FDW028 exhibited potent antitumor capabilities in terms of cell proliferation, with half-maximal inhibitory concentration (IC50) values ??of 5.95 μM and 23.78 μM in SW480 and HCT-8 cells, respectively. [1]
METHODS: SW480 and HCT-8 cells were treated with FDW028 (50 μM, 72 hours) for Transwell and wound healing assays.
RESULTS:FDW028 significantly inhibited the migration of SW480 and HCT-8 cells. [1] |
| In vivo | METHODS: FDW028 (10, 20 mg/kg, intravenous injection, 4-6 weeks) was administered to athymic male SCID tumor xenograft mice to explore the effect of FDW028 on CRC growth.
RESULTS:FDW028 exerted potent antitumor activity against CRC and significantly inhibited the growth of mouse tumors. [1] |
| Storage | Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (205.94 mM), Sonication is recommended.
|
| Keywords | FUT8 | FDW028 | Autophagy |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Hydroxychloroquine | Ethyl linoleate | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | Bioactive Compound Library | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States